AlphAIalphai — Financial news for AI agents
finanznachrichten.deSEP 32 min read$TNGX

Tangram Therapeutics PLC: Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Tangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.

Original reporting
finanznachrichten.de
Published Sep 3, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$TNGX
Bullish
high confidence
Mentioned
$TNGX
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$TNGXBullishMed
01

Why it matters

The trial progression reduces development risk and may attract partnership or financing, influencing valuation.

02

Market read

First‑time disclosure of patient‑cohort dosing for TGM‑312, a material catalyst for the stock.

03

What to watch

Funding runway and competitive pipeline from larger players could limit long‑term upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Tangram Therapeutics is a clinical‑stage biotech developing RNAi medicines; MASH (metabolic dysfunction‑associated steatohepatitis) is a high‑unmet‑need liver disease.

Company-level read

Ticker impact

$TNGXBullishHigh confidence
Context

Tangram Therapeutics announced progression of TGM-312 into patient cohorts in its Phase 1/2 RESTORE-MASH trial.

Expected impact

Potential short‑term upside as investors price in reduced clinical risk.

Evidence & confidence

First disclosure of patient‑cohort dosing; no prior public data on this milestone.

Market effects

Sector

Positive signal for RNAi therapeutics and broader MASH treatment space.

Regional

UK biotech sector may see modest uplift.

Global

Adds credibility to RNAi platform, relevant for investors tracking biotech innovation.

Counterpoint

What could challenge this read

Data read‑out in 2027 could reveal safety issues, tempering early optimism.

Key entities

  • company
    Tangram Therapeutics PLC

    Clinical‑stage biotech developing RNAi therapeutics.

  • executive
    Dr Sonya Montgomery

    New Chief Development Officer overseeing clinical pipeline.

Read at source← All news

Related articles

AUG 11
$TNGXMed

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.

investing.com4 min
AUG 11
$TNGXMed

Tango Therapeutics, Inc. (TNGX): Results of Operations and Financial Condition

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da

SEC EDGAR 8-K4 min
JUL 15
$TNGXMed

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

yahoo.com5 min
JUN 8
$TNGXMedAI 9/10

Tango Therapeutics Announces Proposed $500 Million Public Offering

Tango Therapeutics (Nasdaq: TNGX) announced a proposed underwritten public offering of $500 million of its common stock, with all shares to be sold by the company. The underwriters may be granted a 30-day option to buy up to an additional $75 million of shares. J.P. Morgan, Leerink Partners, Cantor and Stifel are joint bookrunners.

manilatimes.net4 min
JUN 8
$TNGXHighAI 8/10

Tango's Combo Therapy Shows 92% Response In Pancreatic Cancer; Stock Up

Tango Therapeutics (TNGX) shares rose after early Phase 1/2 results for Vopimetostat plus Revolution Medicines’ RAS(ON) inhibitor Daraxonrasib in MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma. The company reported a 92% objective response rate; at six months, 90% were progression-free and median PFS was not reached. Both regimens were generally well tolerated, and Tango plans Phase 3 first-line development later in 2026.

rttnews.com4 min